Results 291 to 300 of about 616,613 (359)
N6‐Methyladenosine (m6A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential
ABSTRACT Accumulating evidence highlights the critical role of epigenetic modifications, particularly N6‐methyladenosine (m6A), in liver disease. As the most abundant RNA modification in eukaryotic cells, m6A is dynamically regulated by multicomponent m6A methyltransferases (e.g., METTL3 and METTL14), demethylases (FTO and ALKBH5), and m6A‐binding ...
Yingfen Chen +6 more
wiley +1 more source
Significant histologic alterations in untreated chronic hepatitis B children: a meta-analysis. [PDF]
Huang C +9 more
europepmc +1 more source
Peripheral and intrahepatic B-cell subsets contribute to HBeAg seroconversion in patients with chronic hepatitis B. [PDF]
Zuo J +6 more
europepmc +1 more source
Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers? [PDF]
Borcak D +9 more
europepmc +1 more source
Elevated serum TIM4 is associated with disease severity and serves as a potential predictive biomarker in chronic hepatitis B. [PDF]
Deng Y +10 more
europepmc +1 more source
Unveiling low level viremia in chronic hepatitis B: challenges and new horizons. [PDF]
Wang B +8 more
europepmc +1 more source
Adherence to antiviral treatment among people living with chronic hepatitis B: A global survey. [PDF]
Block SJ, Ibrahim Y, Cohen C.
europepmc +1 more source

